Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationCurrent Price
as of Oct 18, 2024$1.24
P/E Ratio
N/A
Market Cap
$81.69M
IO Biotech, Inc. engages in the development of immune modulating cancer therapies based on its T-win technology platform. Its platform is a novel approach to cancer immunotherapy designed to activate naturally occurring T cells to target immunosuppressive mechanisms. The company was founded by Mai-Britt Zocca, Inge Marie Svane, and Mads Hald Andersen in December 2014 and is headquartered in Copenhagen, Denmark.
Overview
Trading Information
Company